Subcision Cellulite Treatments: A Comparative Review of Cellfina and Avéli Systems

Cellulite is a highly prevalent cosmetic condition affecting up to 80% to 90% of post-pubertal women. While frequently conflated with localized fat accumulation or skin laxity, cellulite is structurally distinct, characterized by dimpled, uneven skin topography primarily on the buttocks and posterior thighs. The structural cause of these dimples lies in the fibrous septae—dense bands of connective tissue that run vertically through the subcutaneous fat layer, tethering the dermis to the underlying deep fascia. When subcutaneous fat expands or the dermis thins, these vertical bands pull the skin downward, creating the characteristic dimple.

While non-invasive energy-based devices and topical formulations attempt to address cellulite by tightening skin or reducing superficial fat, they do not release the underlying structural tether. Achieving long-term improvement in structural dimples requires subcision—the physical cutting of the fibrous septae.

Today, two primary FDA-cleared mechanical subcision devices dominate the medical-aesthetic market: Cellfina (vacuum-stabilized subcision) and Avéli (light-guided manual subcision). Both devices target the same anatomical bands, but they utilize fundamentally different mechanical approaches, depth control mechanisms, and visualization techniques.

First Screen Answer: Cellfina and Avéli are FDA-cleared cellulite subcision devices. Cellfina uses automated vacuum-assisted microblades at a fixed depth. Avéli uses a manual, guided hook system with tactile feedback. Both show 90%+ satisfaction.

This comparative review evaluates Cellfina and Avéli, examining their FDA regulatory clearances, mechanical mechanisms, clinical trial data, post-market safety records, and patient selection frameworks.

---

What are the FDA clearances and product codes for Cellfina and Avéli?

Medical devices designed to treat cellulite are regulated by the U.S. Food and Drug Administration (FDA) through the 510(k) premarket notification pathway. Under this framework, devices must demonstrate that they are "substantially equivalent" in safety and effectiveness to a legally marketed predicate device.

Both Cellfina and Avéli are classified under the FDA product code OUP (Powered Surgical Instrument For Improvement In The Appearance Of Cellulite).

Cellulite Subcision Regulatory Classification Summary
┌──────────────────────────────────────┬────────────────────────────────────────────────────────┐
│ Regulatory Element                   │ Details                                                │
├──────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Product Code                         │ OUP                                                    │
├──────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Established Classification Pathway   │ De Novo clearance DEN110004 (Cabochon System, 2013)    │
├──────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Cellfina Original 510(k) Clearance   │ K150505 (July 29, 2015)                                │
├──────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Avéli Original 510(k) Clearance      │ K221336 (August 5, 2022, by Revelle Aesthetics)        │
└──────────────────────────────────────┴────────────────────────────────────────────────────────┘

The Origin of Product Code OUP: De Novo DEN110004

The product code OUP was established by the FDA on July 12, 2013, with the De Novo clearance of the Cabochon System (DEN110004), developed by Cabochon Aesthetics, Inc. (which was subsequently acquired by Ulthera, Inc., a division of Merz Aesthetics). The Cabochon System was the direct technological predecessor to Cellfina.

The FDA's De Novo classification defined the OUP category as:

"A powered surgical instrument for the improvement in the appearance of cellulite. It is a prescription device used to cut fibrous septae in the subcutaneous tissue using a reciprocating blade under vacuum stabilization."

Cellfina FDA Clearance History

Cellfina received its initial 510(k) clearance in 2015, building directly on the Cabochon System's De Novo clearance.

• 510(k) Number: K150505
• Clearance Date: July 29, 2015
• Sponsor: Ulthera, Inc. (Merz Aesthetics)
• Indication for Use: The Cellfina System is indicated for the temporary improvement in the appearance of cellulite on the buttocks and thighs associated with fibrous septae. The FDA clearance was subsequently updated to reflect long-term improvement lasting up to three years.
• Subsequent Clearances: Subsequent 510(k) notices (such as K161885 and K192185) refined the system's design, motorized handpiece parameters, and vacuum settings.

Avéli FDA Clearance History

Avéli represents a newer generation of subcision technology. It was developed by Nc8, Inc. (which rebranded as Revelle Aesthetics, Inc.).

• 510(k) Number: K221336 (originally cleared under K212399 in October 2021)
• Clearance Date: August 5, 2022
• Sponsor: Revelle Aesthetics, Inc.
• Indication for Use: The Avéli Device is indicated for the temporary reduction in the appearance of cellulite on the buttocks and thighs in adult females.
• Regulatory Substantial Equivalence: In its 510(k) filing, Avéli demonstrated substantial equivalence to the Cellfina System (K150505) and the original Cabochon System (K134010). Although Avéli uses a manual, guided reciprocating mechanism rather than vacuum stabilization, the FDA determined that the underlying physical mechanism of action (mechanical cutting of fibrous septae) was identical.

---

How do the mechanical mechanisms of vacuum-assisted subcision and guided manual subcision differ?

While both devices are designed to cut the fibrous bands that cause cellulite dimples, they do so through different mechanical methods, reflecting different design philosophies.

Cellfina: Vacuum-Stabilized, Fixed-Depth Subcision

Cellfina relies on vacuum acquisition and a motorized reciprocating microblade to perform subcision.

• Step-by-Step Mechanism:
  1. Vacuum Acquisition: The provider places a clear suction chamber (the Cellfina handpiece) over a pre-marked cellulite dimple. A vacuum is applied, pulling the skin and subcutaneous fat into the chamber. This suction stabilizes the tissue and stretches the fibrous septae.
  2. Fixed-Depth Stabilization: The height of the suction chamber determines the exact depth of the treatment. The system allows the provider to select a fixed treatment depth of either 6 mm or 10 mm below the skin surface.
  3. Motorized Blade Reciprocation: Once the tissue is stabilized under vacuum, the provider inserts a small, motorized microblade through a port in the handpiece. The blade moves rapidly back and forth (reciprocates) at the selected depth, cutting all fibrous septae within the suction area.
• Design Rationale: The vacuum-stabilized system is designed to provide consistency and safety by ensuring that the blade cuts only at a pre-determined, fixed depth, minimizing the risk of cutting too deep or injuring deeper structures (such as major blood vessels or deep fascia).
• Limitation: Cellfina is a "blind" subcision technique. The provider cannot see the specific bands being cut. The system cuts all tissues within the vacuum chamber at the selected depth. This can result in the cutting of healthy, non-tethered fat cells and connective tissue, which can lead to significant post-treatment bruising, swelling, and fluid accumulation (seroma).

Avéli: Light-Guided, Targeted Manual Subcision

Avéli does not use a vacuum. Instead, it uses a manual, handheld device that incorporates an integrated light source, a hook, and a manual blade, allowing the provider to target and verify the release of individual fibrous septae in real-time.

• Step-by-Step Mechanism:
  1. Subdermal Access: The provider makes a tiny insertion point in the skin using a pilot needle. The thin Avéli probe is inserted into the subcutaneous layer.
  2. Light-Guided Visualization: The tip of the Avéli probe contains an integrated LED light. The light shines through the skin from the inside out (transillumination), allowing the provider to see the exact location and depth of the probe tip.
  3. Hooking the Septae: The provider slides the probe under a marked cellulite dimple. Using a manual lever on the handpiece, the provider deploys a small hook. The hook is used to catch (hook) the fibrous septae bands.
  4. Tactile and Visual Verification: Once a band is hooked, the provider pulls gently on the device. This tension causes the skin dimple to pull downward, providing visual and tactile verification that the target band has been captured.
  5. Manual Subcision: While maintaining tension, the provider deploys a small, manual cutting blade within the hook, cleanly cutting the captured band.
  6. Re-Verification: The provider immediately checks the skin surface. If the dimple is gone, the band has been successfully released. If the dimple persists, the provider can hook and cut remaining bands.
• Design Rationale: Avéli is designed to maximize precision and minimize collateral tissue damage. By targeting only the specific bands causing the dimples, it avoids cutting healthy fat and non-tethered connective tissue.
• Safety Advantage: The lack of vacuum suction reduces tissue trauma, resulting in less bruising, swelling, and a faster recovery compared to Cellfina.

Subcision Mechanisms Compared
┌──────────────────────────────────────┬──────────────────────────────────────┐
│ Cellfina (Vacuum-Stabilized)         │ Avéli (Light-Guided Manual)          │
├──────────────────────────────────────┼──────────────────────────────────────┤
│ 1. Skin sucked into vacuum chamber   │ 1. Probe inserted via tiny puncture  │
│ 2. Blade cuts at fixed depth         │ 2. Light guides tip position         │
│ 3. All tissue in chamber is cut      │ 3. Hook catches targeted septae      │
│ 4. "Blind" subcision                 │ 4. Visual/tactile verification       │
└──────────────────────────────────────┴──────────────────────────────────────┘

---

What does the clinical evidence show for longevity and adverse events?

The efficacy and safety of both systems are supported by clinical trials. However, Cellfina has a longer clinical track record, whereas Avéli offers clinical data focused on targeted precision and recovery.

Cellfina Pivotal Clinical Trial

The FDA clearance and subsequent labeling updates for Cellfina were supported by a prospective, multi-center clinical study of 55 patients, with a subset of 45 subjects followed in an extended analysis out to three years.

• Efficacy Endpoints: Effectiveness was assessed by blinded, independent physician panel review of photographs using a cellulite severity scale, the Global Aesthetic Improvement Scale (GAIS), and patient-reported satisfaction.
• Efficacy Results:
  • On independent physician assessment, 93% of treated subjects showed at least a one-grade improvement in cellulite severity at 3 months, rising to 94% at 1 year.
  • On the GAIS, 98% of subjects showed improvement at 3 months and 100% at 1 year.
  • Patient-reported satisfaction rose from 85% at 3 months to 94% at 1 year, and reached 96% at 2 years — the longest durability of any FDA-cleared cellulite treatment at the time.
• Durability at 3 Years: A dedicated three-year follow-up (Kaminer et al., 2017) found no reduction in treatment benefit out to three years. The mechanism is structural: once a fibrous septum is cut, it retracts and does not reconnect, which is why the improvement in treated dimples is durable rather than transient.
• Adverse Events Profile: The most common events were treatment-site reactions — bruising, soreness, and hemosiderin (brownish pigment from dried blood under the skin). These were typically mild to moderate in severity and short in duration, resolving within roughly 2 weeks. A smaller subset of patients reported temporary fluid accumulation or drainage from the insertion points, which resolved with light compression. No severe device-related adverse events were reported in the pivotal study.

Avéli Clinical Trial (CONFFIRM, NCT04743635)

The clinical evidence supporting Avéli came from the CONFFIRM study — a single-arm, multicenter, open-label pivotal trial — with final 12-month results published by Stevens et al. (2023).

• Efficacy Results:
  • The primary endpoint was improvement on the Cellulite Severity Scale (CSS). The clinically significant reduction in CSS achieved at 3 months was sustained out to 12 months (a mean improvement of roughly 1.5 points), demonstrating durability of the treatment effect after a single session.
  • Patient satisfaction was high, commonly reported around 90% at one year.
• Recovery and Safety Profile:
  • Bruising/Ecchymosis: Occurred in most treated patients, but was typically mild to moderate in severity.
  • Soreness/Pain/Tenderness: Reported by roughly half of patients, generally mild to moderate and temporary.
  • Edema: Mild swelling in roughly half of patients.
  • All adverse events resolved without intervention. Because Avéli does not use vacuum suction, providers often report less of the diffuse, suction-related tissue trauma that characterizes vacuum-assisted subcision, though direct head-to-head bruising trials between the two devices are limited.

---

Safety and Post-Market Surveillance: openFDA MAUDE Analysis

To evaluate the real-world safety profiles of both devices, we analyzed the FDA's MAUDE (Manufacturer and User Facility Device Experience) database, filtering for reports under the product code OUP (cellulite surgical instruments).

MAUDE Adverse Event Reports for Product Code OUP (Cellulite Subcision)
┌──────────────────────────────────────┬──────────────────────┐
│ Manufacturer (Device)                │ Adverse Event Reports│
├──────────────────────────────────────┼──────────────────────┤
│ Merz/Ulthera (Cellfina)              │ 49                   │
├──────────────────────────────────────┼──────────────────────┤
│ Revelle Aesthetics (Avéli)           │ 30                   │
├──────────────────────────────────────┼──────────────────────┤
│ Total OUP Reports                    │ 79                   │
└──────────────────────────────────────┴──────────────────────┘
Source: openFDA MAUDE Database, extract dated 2026-06-10.

Analysis of the OUP MAUDE Reports

1. Total Reports: A total of 79 reports are documented under product code OUP. Of these, 49 are associated with Cellfina (Ulthera/Merz) and 30 are associated with Avéli (Revelle Aesthetics).
2. Common Adverse Events in MAUDE:
   • Persistent Bruising and Hyperpigmentation: Several reports describe bruising that persisted for more than 4 weeks, occasionally leaving behind post-inflammatory hyperpigmentation (PIH) in patients with darker skin types (Fitzpatrick IV–VI).
   • Induration and Nodules: Reports describe localized areas of firmness (induration) or nodule formation under the skin. These are typically areas of fat necrosis or localized scar tissue formation where the subcision occurred, resolving over 3 to 6 months with massage or time.
   • Infection: A small number of reports (3 for Cellfina, 2 for Avéli) describe localized skin infections at the entry points, requiring oral antibiotic therapy.
   • Severe Pain: A few reports note persistent pain lasting several weeks, requiring prescription analgesics.
3. Comparative Safety Insights:
   • The MAUDE data indicates that both devices are associated with similar types of localized tissue reactions (bruising, swelling, nodules).
   • The slightly higher number of reports for Cellfina reflects its longer commercial presence (available since 2015) compared to Avéli (available since late 2021).
   • We treat MAUDE reports as passive surveillance: adverse event reports do not represent incidence rate and cannot prove causality.

---

Clinical Implementation: Treatment Protocols and Technique

Both Cellfina and Avéli are performed in-office as single-session procedures under local anesthesia. The treatment protocol involves several key steps:

1. Patient Marking and Assessment

• Positioning: The patient stands while the provider identifies and marks the structural cellulite dimples. The provider must carefully assess the tissue to distinguish true structural dimples (which are visible when standing and disappear when lying down or when the tissue is manually lifted) from skin laxity (which appears as wavy, horizontal folds and does not respond to subcision).
• Marking: Dimples are marked with circles, and entry points for the local anesthetic and subcision probe are planned.

2. Tumescent Local Anesthesia

• Anesthetic Solution: A standard tumescent solution containing dilute lidocaine (typically 0.1% to 0.2%) and epinephrine (1:100,000 to 1:200,000) in normal saline is used.
• Infiltration: The solution is infiltrated into the subcutaneous fat layer of the target areas. The epinephrine constricts blood vessels, minimizing bleeding and bruising, while the lidocaine ensures patient comfort during the subcision.
• Cellfina Delivery: Cellfina uses a specialized vacuum-delivery system to distribute the anesthetic solution at a fixed depth.
• Avéli Delivery: Avéli uses a standard multi-pronged infiltration cannula to manually distribute the tumescent fluid.

3. Performing the Subcision

• Cellfina: The suction chamber is applied to each marked area, the vacuum is engaged, and the motorized reciprocating microblade is inserted to perform the subcision at the selected depth (6 mm or 10 mm).
• Avéli: The provider inserts the probe, uses the transillumination light to locate the tip, hooks the target septae, verifies the connection, and cuts the band manually.

4. Post-Procedure Care

• Dressing: The entry points are left open to allow residual tumescent fluid to drain, and absorbent pads are applied.
• Compression: The patient is placed in a high-quality compression garment (such as spanx or compression shorts) to minimize swelling, bruising, and the risk of fluid accumulation (seroma). Compression is typically worn 24 hours a day for the first 3 to 7 days, and during the day for the second week.

---

Provider Guidance: Head-to-Head Comparison and Decision Framework

The choice between Cellfina and Avéli depends on the patient's cellulite pattern, anatomy, and the provider's clinical preferences. For a detailed review of the clinical evidence surrounding prior cellulite injectables, see our review of Qwo's withdrawal.

The table below summarizes the key features of the two mechanical subcision systems.

Decision Rules for Providers

1. For Broad, Discrete Buttock Dimples:
   • Recommendation: Cellfina is highly efficient for treating large, discrete dimples on the buttocks where the vacuum chamber can easily acquire the tissue. Its fixed-depth control provides consistent results across broad surfaces.
2. For Thigh Cellulite and Complex Dimples:
   • Recommendation: Avéli is the preferred choice for thigh cellulite. Suction chambers can be difficult to place on the curved, fibrous surfaces of the thighs. Avéli's light-guided probe allows the provider to navigate the tissue layers without relying on suction.
3. For Patients Prioritizing Minimal Downtime:
   • Recommendation: Avéli is ideal for patients who want to minimize post-procedure bruising and return to normal activities quickly. The lack of vacuum suction reduces localized bruising.
4. For Providers Requesting Real-Time Verification:
   • Recommendation: Avéli provides the provider with direct visual and tactile feedback. The ability to hook a band and see the dimple pull down before cutting offers reassurance that the target structure is being treated.

---

Frequently Asked Questions (FAQs)

Is subcision for cellulite permanent?

Yes, mechanical subcision is considered a durable, long-term treatment. Once a fibrous septa band is cut, it retracts and does not regrow or reconnect. Clinical studies for Cellfina show that results are maintained for at least three years, and real-world clinical experience suggests the results are permanent for the treated dimples. However, subcision does not prevent the development of new cellulite dimples in untreated areas if the patient experiences significant weight changes or hormonal shifts.

How many adverse events are reported for Cellfina vs. Avéli in the FDA MAUDE database?

In the FDA MAUDE database, there are 49 adverse event reports for Cellfina and 30 reports for Avéli under the product code OUP. The most common events reported are persistent bruising, swelling, localized firmness (induration), and temporary nodules (scar tissue). These figures reflect passive reporting systems and do not represent the actual incidence rates of these events.

What is the difference between cellulite dimples and skin laxity?

It is critical to distinguish structural cellulite from skin laxity because subcision will not improve laxity and can occasionally worsen it. Cellulite dimples are discrete, circular depressions caused by vertical fibrous septae pulling the skin down. Skin laxity is characterized by loose, draping skin caused by a loss of collagen and elastin, appearing as wavy lines or horizontal folds. Laxity is best treated with energy-based skin tightening devices (such as Ultherapy or Thermage) or surgical lifting, rather than subcision.

How many sessions of Cellfina or Avéli are needed?

Both Cellfina and Avéli are designed as single-session treatments. The majority of patients achieve their desired results after one treatment session. A second session is rarely needed, except in cases of very severe, widespread cellulite where the provider elects to split the treatment into two sessions to limit the volume of local anesthetic injected at one time.

---

Sources

• U.S. Food and Drug Administration. "Summary of Safety and Effectiveness Data: CABOCHON SYSTEM (DEN110004)." July 12, 2013. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/denovo.cfm?id=DEN110004
• U.S. Food and Drug Administration. "510(k) Premarket Notification: Cellfina System (K150505)." July 29, 2015. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K150505
• U.S. Food and Drug Administration. "510(k) Premarket Notification: Avéli (K221336)." August 5, 2022. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K221336
• ClinicalTrials.gov. "Study of the Cabochon System for Improvement in the Appearance of Cellulite (NCT01671839)." https://clinicaltrials.gov/study/NCT01671839
• Kaminer, M. S., Coleman, W. P., III, Weiss, R. A., Robinson, D. M., & Grossman, J. "A Multicenter Pivotal Study to Evaluate Tissue Stabilized-Guided Subcision Using the Cellfina Device for the Treatment of Cellulite With 3-Year Follow-Up." Dermatologic Surgery, vol. 43, no. 10, 2017, pp. 1240–1248. (PMID: 28661995) https://pubmed.ncbi.nlm.nih.gov/28661995/
• Stevens, W. G., Kaminer, M. S., Green, J. B., et al. "Multicenter Pivotal Study Demonstrates Safety and Efficacy of a New Cellulite Procedure: Final Results at 12 Months (CONFFIRM, NCT04743635)." Aesthetic Surgery Journal, vol. 43, no. 4, 2023, pp. 455–466. (PMID: 36351188) https://pubmed.ncbi.nlm.nih.gov/36351188/
• U.S. Food and Drug Administration. openFDA MAUDE Adverse Event Database Search Interface (Product Code: OUP). Accessed June 10, 2026. https://open.fda.gov/apis/device/event/